Protalix Biotherapeutics Down 8.65% To $1.59 After Earnings

reported that it broke-even during the quarter.



The stock is down 8.65% to $1.59 after the report.

Protalix Biotherapeutics's profit margins maintained as both earnings and revenue declined at the same pace.

The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.

Trading in the five days leading up to the report earned Protalix Biotherapeutics a Bullish Sentiment Rank from InvestorsObserver.

Protalix Biotherapeutics has performed a little above average during the past few months. Before the report, Protalix Biotherapeutics received a Long-Term Technical Rank by InvestorsObserver of 62, putting it in the top half of stocks. The firm set a 52-week high on May 5, 2023 at $3.55 and set a 52-week low on November 10, 2022 at $1.

Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis.The company's primary sources of revenues include its sales of taliglucerase alfa in Brazil and of drug substance to Pfizer under its Amended Pfizer Agreement.